FDA Issues Warning Letter to Chemspec Chemicals Private Limited

In January 2026, the U.S. FDA issued a Warning Letter to Indian firm Chemspec Chemicals Private Limited following an inspection conducted in July–August 2025. The letter cites a major CGMP violation regarding the company’s Active Pharmaceutical Ingredients (APIs) and intermediates:

• Failure of the quality unit to ensure compliance with CGMP standards.

The FDA highlighted deficiencies in quality oversight, documentation practices, and data integrity, including:

• Missing reviews and releases of multiple API batches
• Incomplete or absent batch production records
• No investigations initiated for deviations
• Repeated data integrity lapses

The Warning Letter recommends extensive remediation and CAPA measures and strongly advises engaging a qualified consultant to address these issues.

The FDA concluded that it may refuse admission of substances produced at Chemspec until compliance is ensured.

For the full list of violations and the FDA’s conclusions, refer to the official Warning Letter for Chemspec Chemicals Private Limited.

21-01-2026